Agenus (Formerly known as Antigenics Inc. - New York)
Corporate Headquarters
3 Forbes Road
Lexington
Massachusetts
02421-7305
United States
Tel: 781-674-4400
Fax: 781-674-4200
Website: http://www.agenusbio.com/
Email: info@antigenics.com
108 articles about Agenus (Formerly known as Antigenics Inc. - New York)
-
Agenus Reports Second Quarter 2017 Financial Results And Provides Corporate Update
8/3/2017
-
Agenus To Report Second Quarter 2017 Financial Results On August 3, 2017; Conference Call To Follow
7/27/2017
-
Agenus To Report First Quarter 2017 Financial Results On May 4, 2017; Conference Call To Follow
4/27/2017
-
Agenus Release: Company Announces Collaboration With The NCI To Evaluate The Combination Of Pembrolizumab (Keytruda, Merck & Co.) With Prophage (Agenus Inc.) Autologous Vaccine
1/17/2017
-
Agenus To Report Third Quarter 2016 Financial Results On October 27, 2016; Conference Call To Follow
10/20/2016
-
Agenus To Present At The Rodman & Renshaw 18th Annual Global Investment Conference
9/6/2016
-
Agenus Appoints Jean-Marie Cuillerot, M.D. As Vice President And Global Head Of Clinical Development
7/6/2016
-
Agenus Announces Commencement Of Phase I/II Clinical Trial Of Anti-GITR Checkpoint Antibody INCAGN1876 In Patients With Solid Tumors
6/22/2016
-
Agenus Reports Fourth Quarter And Full Year 2015 Financial And Operational Results And Recent Highlights
3/3/2016
-
Agenus Bags Novel Antibodies to Immuno-oncology Target for $44 Million+
7/20/2015
-
Agenus To Present At The Cowen and Company 35th Annual Health Care Conference
2/26/2015
-
Agenus Reports Third Quarter 2014 Financial Results
10/31/2014
-
Agenus Reports Second Quarter 2014 Financial Results
7/24/2014
-
Massachusetts' Agenus Touts Positive Phase 2 Data From HerpV Study
6/26/2014
-
Agenus (Formerly known as Antigenics Inc. - New York) Completes Acquisition of 4-Antibody AG
2/13/2014
-
Agenus (Formerly known as Antigenics Inc. - New York)’ Prophage Vaccine For Glioma Hailed As A "Very Promising Therapy" In An Editorial Published In The Journal Neuro-Oncology
1/21/2014
-
Agenus (Formerly known as Antigenics Inc. - New York) To Present At OneMedForum San Francisco 2014
1/9/2014
-
Agenus (Formerly known as Antigenics Inc. - New York)' Brain Cancer Vaccine Program Named A "Top Project To Watch" By Elsevier Business Intelligence
11/18/2013
-
Agenus Reports Third Quarter 2013 Financial Results
10/24/2013
-
Agenus (Formerly known as Antigenics Inc. - Lexington, MA) Reports Positive Follow-on Phase 2 Results for Brain Cancer Vaccine in Newly Diagnosed Patients
9/17/2013